A blood pressure drug cut urine protein 52% vs. placebo among people with kidney disease and protein in their urine.
Mineralys Therapeutics (MLYS) presented Phase 3 trial data showing lorundrostat reduced systolic blood pressure and urine protein in CKD patients. The drug cut SBP by 9.6 mmHg in CKD patients and 12.2 mmHg in others, with a 52% reduction in urine protein. The company aims to target hypertension and related comorbidities.
How this was made
The 30-second read
Why it matters
The trial showed a 9.6‑mmHg placebo‑adjusted SBP reduction in CKD patients and a 52% reduction in urine albumin‑to‑creatinine ratio, indicating potential disease‑modifying benefits.
Market read
First public disclosure of pivotal trial data; likely to move MLYS and influence peers in the hypertension/CKD space.
What to watch
regulatory timeline, competitive landscape, and need for long‑term safety data could temper the rally
Background
Mineralys Therapeutics announced Phase 3 trial results for lorundrostat, an aldosterone synthase inhibitor targeting uncontrolled hypertension and CKD.
Ticker impact
Phase 3 Launch-HTN trial data shows lorundrostat reduces systolic BP and albuminuria in CKD patients.
likely upside as market prices in the favorable Phase 3 data
First disclosure of statistically significant BP and albuminuria reductions; investors typically reward such data.
Market effects
could boost the hypertension and CKD therapeutic sector as a new mechanism gains validation
supports US biotech sentiment, especially for companies targeting aldosterone pathways
relevant to global pharma investors tracking novel antihypertensive pipelines
Counterpoint
data may not translate into FDA approval or commercial success, risking overvaluation
Key entities
- companyMineralys Therapeutics, Inc.
US‑listed biotech developing lorundrostat for hypertension and CKD.
- drug_candidateLorundrostat
Investigational aldosterone synthase inhibitor in Phase 3.
